The US FDA consulted with a hemophilia patient advocate about the benefit/risk profile of Genentech Inc.'s Hemlibra (emicizumab-kxwh) in light of serious cases of thrombotic microangiopathy and thromboembolic events that had temporarily halted clinical trial enrollment.
Although the patient advocate – Christopher Templin, a special government employee who has participated in FDA advisory committee meetings –...







